Australia's largest stock trading and investment forum Australia's #1 stock forum

ALT

0.00%

0.5¢ analytica limited

Strategic Review - Urgently Required, page-4

First 4 Last

Share
Profile

Follow
baanya

134 Posts.

4

01/02/16

11:41

Post #: 16912285
Share

Originally posted by Last of the Mohicans ↑

Having had some more time to digest the quarterly report, its apparent to me that a Strategic Review is Urgently Required.

The strategy currently in place is clearly not working & is unsustainable given the company's current financial position.

I'm still trying to work out why the USA FDA would even mention the company's product in the way that it did when the company's only managed to sell @ 524 in the last 6 months & maybe 1000 units in total.

At the current rate of expenditure there is not enough money left for the company to last another 4 months.

6 months of advertising & marketing have used up A$1.5M of cash to achieve just A$0.131M of sales.

I'm going to propose something radical, for other shareholders to debate. (yes I'm sure it will need tweaked slightly)

We should be telling the board of directors to immediately suspend all advertising & marketing (A&M) other than the signing of distribution agreements (like the UK one) one for AUS & maybe two for USA.

The PeriCoach device will be sold for the next 6 months @ A$100 per unit.

The software and App subscription will be set at A$48 per year.

Those that have already purchased the PeriCoach device will be credited with 2 additional year's subscription (free of charge).

Yes it will cost the company money to do this (effectively in supermarket terms, a loss leader product) however it will cost far less than we've just spent on A&M (and got little in return for it).

I'd like to think it will result in sales of 10,000 units over the 6 month period.

Those buying the product during the period will be required to have there data used by the company (anonymously) for research purposes, to improve the product further & for the study.

They'll also be asked if they would mind submitting a short survey after 3 & 6 months to pass on there own views of the product & its performance in there own circumstances, so that it can be compared to the data from the study . The purpose being to see that what appears to be improvements in pelvic floor muscle strength data wise etc is actually translating into visible improvements in the daily lifestyle of the user.

Having that amount of data available to the study group should allow them to clearly see what benefits are occurring etc etc

LOTM

Expand

This is truly a stupid suggestion! would only scare off any potential business partners / distributors as well as showing a frightful share holder base and causing an even greater financial loss.
Im not endorsing the current direction of management but such drastic action as suggested is insane!

No company would want to deal with ALT under that scenario.

ALT Price at posting: 0.5¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Breaking news: New opportunities for investors & companies - HotCopper opens to capital raising!

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

There are more pages in this discussion • 28 more messages in this thread...

First 4 Last

Add ALT (ASX) to my watchlist

Strategic Review - Urgently Required, page-4

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Breaking news: New opportunities for investors & companies - HotCopper opens to capital raising!

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Featured News